DVAX: Rasio kapitalisasi marang pendapatan Dynavax Technologies

Simbol lan logo merek Dynavax Pharma (DVAX)

Dynavax Technologies (DVAX) enjoys high physician confidence following the success of its hepatitis B vaccine. The price-to-sales ratio reflects the current market valuation, with the metric standing at 5.50. The business is protected by the mandatory nature of immunization, which ensures stability. However, reliance on a single flagship product and sector pressure create certain risks for growth.

DVAX Rasio rega marang pendapatan Dynavax Technologies Corp (04.07.2022 - 21.02.2026)

Dynavax Corp (DVAX) - rincian metrik lan laporan keuangan

- rega saham lan konsensus proyeksi valuasi:
Bagan owah-owahan rega Dynavax Technologies Corporation|DVAX - Prakiraan konsensus analis
- informasi kapitalisasi pasar:
Kapitalisasi pasar Dynavax Corp|DVAX - Rega Nyata Tumbas Perusahaan Kanthi Wutuh
- rincian valuasi buku bisnis:
Nilai Aset Bersih saben Saham Dynavax|DVAX - Nilai Buku Perusahaan|Rasio Kapitalisasi marang Nilai Buku dynavax.com|DVAX - Total Aset Perusahaan
- rincian struktur utang lan likuiditas bisnis:
Total Utang marang Modal Dynavax Technologies|DVAX - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang ekuitas Dynavax Pharma|DVAX - Gunggung utang perusahaan|Utang-utang marang kapitalisasi buku Dynavax Corp|DVAX - Kewajiban jangka dawa perusahaan|Tanggungan utang jangka cendhak perusahaan Dynavax|Rasio jangkoan perantara dynavax.com
- data bathi lan kelipatan valuasi:
DVAX - Penghasilan resik|Bathi resik mangsa ngarep Dynavax Technologies|DVAX - Pangali P/E|Rasio prakiraan rega marang bathi Dynavax|DVAX - Pangali PEG|Rasio nilai perusahaan marang bathi sadurunge bunga, pajeg, lan panyusutan Dynavax Corp|DVAX - Bathi operasional EBITDA|Bathi saben saham sajroning taun lumaku Dynavax|DVAX - Bathi saben saham sajrone rolas wulan pungkasan|Wutah bathi saben saham taun-ka-taun sajrone 12 wulan pungkasan dynavax.com|DVAX - Wutah bathi saben saham ing taun lumaku|Prakiraan wutah bathi resik saben saham ing taun ngarep Dynavax Technologies
- data total pendapatan lan volume dodolan:
DVAX - Pendapatan perusahaan|Prakiraan pendapatan perusahaan Dynavax Corp|DVAX - Rasio rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Dynavax Corp
Analisis umum perusahaan:DVAX dynavax.com
Produk mawa merek Dynavax Pharma

When selecting defensive assets, investors seek a combination of stable cash flow and fair market value. For Dynavax Technologies (DVAX), scaling Heplisav-B vaccine sales creates operating leverage, making the market cap-to-revenue ratio a key indicator for assessing technology monetization efficiency and the extent of the premium paid for future earnings growth relative to current operating sales.

Karo sapa Dynavax Technologies saingan

ARWR (arrowheadpharma.com) - Rasio kapitalisasi pasar marang pendapatan|Multiplikator P/S MIRM (Mirum)|ABUS: Rasio kapitalisasi marang pendapatan|IVA: Kapitalisasi marang pendapatan|Rega marang dodolan Gyre Therapeutics Corp.|Assembly Biosciences (ASMB) - Rasio rega marang pendapatan|Rasio kapitalisasi marang pendapatan GALT|GNFT (Genfit SA) - Multiplikator P/S|Multiplikator P/S DURECT Corp.|Kapitalisasi marang pendapatan ALGS (Aligos Therapeutics)|Rasio rega marang pendapatan BIVI (biovieinc.com)|Multiplikator P/S GLMD (Galmed Pharmaceuticals Ltd.)|Multiplikator P/S endrainc.com NDRA|HEPA: Kapitalisasi marang pendapatan